NCT03534180View on ClinicalTrials.gov

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 21, 2018

Primary Completion Date

April 21, 2021

Study Completion Date

July 26, 2023

Conditions
Anaplastic Large Cell LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Romidepsin

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (2)

68198

University of Nebraska Medical Center, Omaha

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03534180 - Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | Biotech Hunter | Biotech Hunter